Sana Biotechnology Inc (SANA)

Currency in USD
4.16
-0.11(-2.46%)
Real-time Data·
SANA Scorecard
Full Analysis
Quickly burning through cash
Earnings results expected today
SANA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.094.28
52 wk Range
1.267.30
Key Statistics
Prev. Close
4.26
Open
4.28
Day's Range
4.09-4.28
52 wk Range
1.26-7.3
Volume
887.17K
Average Volume (3m)
4.92M
1-Year Change
-11.98%
Book Value / Share
0.93
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SANA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.33
Upside
+124.36%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Sana Biotechnology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Sana Biotechnology Inc Company Profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin’s lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology Inc SWOT Analysis


Innovative Platform
Sana's hypoimmune platform technology aims to revolutionize cell therapy, potentially eliminating the need for immunosuppression in patients
T1D Breakthrough
Explore Sana's promising UP421 program, showing insulin production after 24 weeks without immunosuppression in Type 1 Diabetes treatment
Market Potential
Analyst consensus suggests significant upside, with price targets ranging from $5 to $15 per share for this clinical-stage biotechnology company
Competitive Landscape
Delve into Sana's strategic positioning in the crowded autoimmune disease space, balancing unique off-the-shelf products against established players
Read full SWOT analysis

Compare SANA to Peers and Sector

Metrics to compare
SANA
Peers
Sector
Relationship
P/E Ratio
−4.5x−3.5x−0.5x
PEG Ratio
−0.11−0.010.00
Price/Book
4.5x2.6x2.6x
Price / LTM Sales
-161.8x3.3x
Upside (Analyst Target)
111.3%178.2%42.8%
Fair Value Upside
Unlock−0.5%6.5%Unlock

Analyst Ratings

7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 9.33
(+124.36% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.21 / -0.24
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SANA Income Statement

People Also Watch

34.69
BMNR
+4.17%
6.760
BBAI
-3.98%
46.245
SMR
+2.47%
52.235
ASTS
-0.64%
25.34
CNC
-2.12%

FAQ

What Stock Exchange Does Sana Biotechnology Trade On?

Sana Biotechnology is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Sana Biotechnology?

The stock symbol for Sana Biotechnology is "SANA."

What Is the Sana Biotechnology Market Cap?

As of today, Sana Biotechnology market cap is 933.80M.

What Is Sana Biotechnology's Earnings Per Share (TTM)?

The Sana Biotechnology EPS (TTM) is -0.88.

When Is the Next Sana Biotechnology Earnings Date?

Sana Biotechnology will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is SANA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Sana Biotechnology Stock Split?

Sana Biotechnology has split 0 times.

How Many Employees Does Sana Biotechnology Have?

Sana Biotechnology has 194 employees.

What is the current trading status of Sana Biotechnology (SANA)?

As of 06 Aug 2025, Sana Biotechnology (SANA) is trading at a price of 4.16, with a previous close of 4.26. The stock has fluctuated within a day range of 4.09 to 4.28, while its 52-week range spans from 1.26 to 7.30.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.